Nov 14, 2016
LT3001 Presented at Stroke Forum
Taiwan Stroke Society held its 2016 Annual Meeting and the inaugural “Asia Pacific Stroke Forum" (hereafter referred to as “the Forum”) on November 12 and 13 in The Grand Hotel, Taipei. Stroke specialists and key opinion leaders all over the world were invited to discuss the newest stroke treatment methods. Dr. Sheng-Wen Yeh of Lumosa Therapeutics (Lumosa, TPEx:6535) was invited to give an orally presentation on the findings in a recent non-primate study of LT3001, a novel chemical entity under development by Lumosa for the treatment of acute ischemic stroke.
Cerebral stroke is the second leading cause of death globally, one in six persons in the world suffers from stroke. Approximately 170 thousand people per year in Taiwan suffered stroke, which is not only the leading cause of disability, but one of the most disease conditions to drain healthcare resources and cause economic burden to patients’ family. About 80% of all strokes are acute ischemic stroke. The market for acute ischemic stroke treatment is estimated to be worth US$15 billion. Lumosa’s LT3001 treats acute ischemic stroke caused by blood clots in arteries.
Dr. Yeh's presentation during the session on Bench to Clinical Practice included study results generated independently from researchers at Lumosa, China Medical University, National Taiwan University, and Harvard University. LT3001 effectively dissolves blood clot, and reduces the volume of the embolism without altering coagulation time.
“Since the approval of rt-PA 20 years ago, the medical field continues to search for an safe and effective therapy for acute ischemic stroke.” said by Dr. Wendy Huang, CEO of Lumosa Therapeutics. “LT3001 is the only small molecule new drug that combines thrombolytic and neuroprotective functions under development for the unmet medical need. We are honored to be invited to present our findings in the first Asia Pacific Stroke Forum sponsored by Taiwan Stroke Society. Lumosa plans to submit IND to the US FDA in 2017.”
Source：Lumosa Therapeutics Co., Ltd.
http://www.lumosa.com.tw/en/News/Pipeline/LT3001-Asia+Pacific+Stroke+Forum